What Has Been the Progress and Growth of the Enbrel Market in Recent Years?
The enbrel market has seen considerable growth due to a variety of factors.
• The market size of Enbrel has seen significant growth in the last couple of years. The market which was valued at $15,876.25 million in 2024 is projected to rise to $16,825.42 million in 2025, with a Compound Annual Growth Rate (CAGR) of 6.0%.
Factors contributing to this growth during the preceding period include a rising occurrence of rheumatoid arthritis, a growing requirement for tailor-made treatments of autoimmune disorders, a surge in demand for superior biologic therapies, an increase in health investments in biologics and an aging population.
What Can Be Expected from the Enbrel Market Size?
The enbrel market is expected to maintain its strong growth trajectory in upcoming years.
• Expect robust expansion in the enbrel market size over the next couple of years, as projections predict a growth to $20,930.93 million by 2029 and a Compound Annual Growth Rate (CAGR) of 5.6%.
This growth within the forecast period could be a result of the escalating use of enbrel across various indications, raised support for biologics and rheumatoid arthritis (ra) treatments by governments, heightened recognition of autoimmune diseases, increasing public knowledge of inflammatory diseases, improved access to biosimilars, and boosted awareness concerning enbrel. The upcoming trend within the period looks promising with the introduction of digital healthcare tools designed to manage autoimmune diseases, global collaborations between pharmaceutical companies, the creation of long-acting injectable formulations for enhanced patient compliance, application of artificial intelligence in creating drugs for autoimmune diseases, and the evolution of alternative delivery channels for biologic drugs.
What Are the Critical Driver Fuelling The Enbrel Market's Growth?
The rising instances of autoimmune conditions are anticipated to fuel the growth of the enbrel market in the coming times. Autoimmune conditions emerge when the immune system erroneously attacks the body's own healthy cells and tissues, causing inflammation and damage to multiple organs. The heightened instances of autoimmune conditions can be credited to factors like genetic susceptibility, environmental catalysts, and alterations in lifestyle and immune system function. The growing abundance of such conditions stimulates the need for treatments such as Enbrel, which are effective in managing conditions like rheumatoid arthritis and psoriatic arthritis. For instance, the National Library of Medicine, a US-based medical library, reported in August 2022 that there were approximately 928 cases of autoimmune conditions related to COVID-19 vaccination in 2022. Out of these, 81.5% or 756 cases were newly diagnosed autoimmune diseases, the symptoms of which generally appeared eight days after vaccination. Women, constituting 53.6% of cases, were primarily impacted with the median age being 48. Therefore, the escalating instances of autoimmune conditions are set to propel the enbrel market.
How Is The Enbrel Market segmented?
The enbrel market covered in this report is segmented –
1) By Product: Injectable Solution, Prefilled Syringes, Combination Therapy, Extended Release Formulations, Biosimilars
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By Application: Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Other Applications
Pre-Book The Enbrel Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are Emerging Trends Reshaping The Dynamics Of The Enbrel Market?
A significant trend in the enbrel market is securing drug approval from regulatory bodies to strengthen industry competitiveness. The procedure of drug approval involves regulatory authorities scrutinizing and authorizing a novel drug for sale and use, thereby assuring its safety, effectiveness, and quality based on clinical trial data. For example, Amgen Inc., a United States-based biopharmaceutical company, unveiled the approval of Enbrel by the U.S. Food and Drug Administration (FDA) in October 2023, aimed at managing children aged two or older suffering from active juvenile psoriatic arthritis (JPsA). This approval showcases the distinctive attribute of etanercept, a tumor necrosis factor blocker, which was proven in extensiveness safety and effectiveness studies in adult patients with psoriatic arthritis (PsA), rheumatoid arthritis (RA), and psoriasis. This also encompasses pharmacokinetic (PK) data that validates its use in pediatric patients with active juvenile idiopathic arthritis (JIA) and psoriasis. The prescribed dosage for juvenile PsA (JPsA) is adjusted according to body weight and is administered through weekly subcutaneous injection.
Who Are the Key Players In The Enbrel Market?
Major companies operating in the enbrel market are:
• Amgen Inc.
What Is The Most Dominant Region In The Enbrel Market?
North America was the largest region in the enbrel market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the enbrel market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
